Artificial Intelligence Platform Helps Find Combination Drug Treatments for COVID-19
By HospiMedica International staff writers Posted on 08 Apr 2020 |

Image: AI powered drug discovery (Photo courtesy of Healx)
Healx (Cambridge, UK), an AI-powered biotech company specializing in rare diseases, is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Many patients in this demographic suffer from pre-existing conditions relating to the heart and respiratory system which have been associated with the highest mortality rates amongst COVID-19 patients. Given this increased vulnerability to COVID-19, and the acute need for treatments, Healx is dedicating its time, knowledge, experience and technology towards fighting the viral infection. The treatments Healx intends to develop are also likely to have wide use amongst other patients identified as vulnerable.
Healx’s AI platform, Healnet, integrates and analyzes biomedical data from multiple sources to predict those combination therapies that are most likely to succeed in the clinic. The company’s AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Healnet is widely regarded as the world’s most efficient and comprehensive AI platform for rare diseases. Combination therapy candidates will be available in May for preclinical testing.
“The recent spread of COVID-19 is risking the lives of millions of rare disease patients across the world. The company’s AI technology is perfectly positioned to support the efforts to find treatments for COVID-19. Healx’s data-driven AI platform is able to predict, within weeks, which known drugs can be repurposed to treat other conditions such as COVID-19,” said Dr. David Brown, Healx Chairman and Co-founder. “This approach significantly shortens discovery-to-clinic timelines. Our AI is able to combine 2-3 existing drugs to formulate the most effective treatment. This approach ensures that any potential treatments we identify can be used by clinicians to help patients very quickly.”
Related Links:
Healx
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Many patients in this demographic suffer from pre-existing conditions relating to the heart and respiratory system which have been associated with the highest mortality rates amongst COVID-19 patients. Given this increased vulnerability to COVID-19, and the acute need for treatments, Healx is dedicating its time, knowledge, experience and technology towards fighting the viral infection. The treatments Healx intends to develop are also likely to have wide use amongst other patients identified as vulnerable.
Healx’s AI platform, Healnet, integrates and analyzes biomedical data from multiple sources to predict those combination therapies that are most likely to succeed in the clinic. The company’s AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Healnet is widely regarded as the world’s most efficient and comprehensive AI platform for rare diseases. Combination therapy candidates will be available in May for preclinical testing.
“The recent spread of COVID-19 is risking the lives of millions of rare disease patients across the world. The company’s AI technology is perfectly positioned to support the efforts to find treatments for COVID-19. Healx’s data-driven AI platform is able to predict, within weeks, which known drugs can be repurposed to treat other conditions such as COVID-19,” said Dr. David Brown, Healx Chairman and Co-founder. “This approach significantly shortens discovery-to-clinic timelines. Our AI is able to combine 2-3 existing drugs to formulate the most effective treatment. This approach ensures that any potential treatments we identify can be used by clinicians to help patients very quickly.”
Related Links:
Healx
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
Discovery of Heart’s Hidden Geometry to Revolutionize ECG Interpretation
Electrocardiograms (ECGs) are one of the most widely used tools in diagnosing heart conditions, but their accuracy can be affected by natural variations in individual heart anatomy. Traditional ECG interpretation... Read more
New Approach Improves Diagnostic Accuracy for Esophageal Motility Disorders
Esophageal motility disorders are conditions in which the muscles of the esophagus fail to function properly, often resulting in difficulty swallowing. Diagnosing these disorders can be challenging, as... Read more
Wristband Sensor Provides All-In-One Monitoring for Diabetes and Cardiovascular Care
Diabetes management is a complex and evolving challenge, particularly when it comes to accurately tracking and understanding how various factors affect blood sugar levels and overall health.... Read more
Handheld Device Enables Imaging and Treatment of Oral Cancer in Low-Resource Settings
Oral cancer is a growing public health concern, particularly in South Asia, where it affects tens of thousands of people each year. In India, oral cancer accounts for 40% of all cancers, largely driven... Read moreSurgical Techniques
view channel
Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery
Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more
LED-Based Imaging System Could Transform Cancer Detection in Endoscopy
Gastrointestinal cancers remain one of the most common and challenging forms of cancer to diagnose accurately. Despite the widespread use of endoscopy for screening and diagnosis, the procedure still misses... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more